Last reviewed · How we verify
Coenzyme I (NADIDE)
NADIDE, a marketed form of Coenzyme I, is positioned in the market with a mechanism that influences cellular energy production. A key strength is its patent protection, which extends until 2028, providing a period of exclusivity. The primary risk is the lack of specified primary indication and revenue data, which may limit strategic planning and investor confidence.
At a glance
| Generic name | NADIDE |
|---|---|
| Drug class | Vitamin C [EPC] |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Brain NAD in Alzheimer's Disease
- A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors (PHASE1,PHASE2)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- NAD+ Oral Supplement Pilot Intervention in Adult Females (NA)
- NAD Supplementation and Vascular Health in PAD (PHASE1,PHASE2)
- NAD+ and Exercise in FA (NA)
- Sirtuin-NAD Activator in Alzheimer's Disease (PHASE1,PHASE2)
- PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coenzyme I CI brief — competitive landscape report
- Coenzyme I updates RSS · CI watch RSS